TheraPEAKTM X-VIVOTM 15 Serum-free Hematopoietic Cell Medium
TheraPEAKTM X-VIVOTM 15 Serum-free Hematopoietic Cell Medium
TheraPEAKTMX-VIVOTM 15, Serum-free hematopoietic cell medium, with L-Glutamine, without gentamicin and phenol red, xenofree, 1L bag
Want to request a quote or find our more information about this product including customization options? Please fill in your request and your local sales specialist will contact you.
Product Overview
TheraPEAKTM X-VIVOTM 15 is a high performing media that provides nutritionally adequate and balanced environments for a variety of hematopoietic cells including:
- T cells Natural killer cells (NK)
- Peripheral blood lymphocytes (PBL)
- Tumor infiltrating lymphocytes (TIL)
- Dendritic cells (DC)
- Human monocytes Macrophage cells
TheraPEAKTM X-VIVOTM 15 Media are mostly known for its ability to support the proliferation of purified CD3+ cells isolated from peripheral blood and human tumors making it well suited for CAR-T applications.
TheraPEAKTM X-VIVOTM 15 Media are similar in composition to X-VIVOTM 10 Media but is better suited for rapidly growing cells, specifically cells of the immune system.
All TheraPEAKTM Products are produced according to applicable GMP standards and follow the USP/EP guidance for cell and gene therapy raw materials. It is the end user's responsibility to ensure full compliance with local regulations in terms of safety assessments and effective removal prior to patient exposure.
TheraPEAKTM Media Products are produced according to applicable GMP raw material standards and are intended to support GMP manufacturing. TheraPEAKTM Media Products are produced at FDA registered manufacturing sites with an ISO 13485 certified quality management system.
Request More InfoBenefits
- Superior media for most hematopoietic cells types including dendritic cells, lymphocytes, monocytes, macrophages and granulocytes.
- Formulations only contain human derived components
- More regulatory friendly as human component is replaced by a recombinant one
- Highly cited in scientific literature
- Clinical proven formulations providing process safety and constancy
- High productivity resulting in a high viable cell yield
- Serum Free media result in a more defined process and result in limited immune response
- Efficient transgene expression
- Desirable T-cell phenotype
Applications
- Proliferation of peripheral blood lymphocytes
- Proliferation of tumor infiltrating lymphocytes
- Cultivation of human monocytes and macrophages
- Cultivation of stem cells
- Cultivation of CAR-T cells
SDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cells
A strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells. -
A Non-Viral Method for Modifying and Expanding Primary T Cells
Learn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow. -
Case Study – Improving the Expansion of Patients' T Cells
In this serum-free media case study, learn how selection of memory T cells can aid in streamlining CAR-T therapies.